A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma

Abstract excerpt

BACKGROUND: Several studies showed that gain-of-function somatic mutations affecting the catalytic domain of EGFR in non-small cell lung carcinomas were associated with response to gefitinib and erlotinib, both EGFR-tyrosine kinase inhibitors. In addition, 4% of non-small cell lung carcinomas were shown to have ERBB2 mutations in the kinase domain. In our study, we sought to determine if similar respective...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Colorectal Cancer Treatments and Studies
• Share to Hepatocellular Carcinoma Treatment and Prognosis
• Share to Lung Cancer Treatments and Mutations